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ABSTRACT
Background Adult community-acquired pneumonia
(CAP) is a relevant worldwide cause of morbidity and
mortality, however the aetiology often remains uncertain
and the therapy is empirical. We applied conventional
and molecular diagnostics to identify viruses and atypical
bacteria associated with CAP in Chile.
Methods We used sputum and blood cultures,
IgG/IgM serology and molecular diagnostic techniques
(PCR, reverse transcriptase PCR) for detection of
classical and atypical bacteria (Mycoplasma pneumoniae,
Chlamydia pneumoniae, Legionella pneumoniae) and
respiratory viruses (adenovirus, respiratory syncytial virus
(RSV), human metapneumovirus, inﬂuenza virus,
parainﬂuenzavirus, rhinovirus, coronavirus) in adults
>18 years old presenting with CAP in Santiago from
February 2005 to September 2007. Severity was
qualiﬁed at admission by Fine’s pneumonia severity
index.
Results Overall detection in 356 enrolled adults were
92 (26%) cases of a single bacterial pathogen, 80
(22%) cases of a single viral pathogen, 60 (17%) cases
with mixed bacterial and viral infection and 124 (35%)
cases with no identiﬁed pathogen. Streptococcus
pneumoniae and RSV were the most common bacterial
and viral pathogens identiﬁed. Infectious agent detection
by PCR provided greater sensitivity than conventional
techniques. To our surprise, no relationship was
observed between clinical severity and sole or
coinfections.
Conclusions The use of molecular diagnostics
expanded the detection of viruses and atypical bacteria
in adults with CAP, as unique or coinfections. Clinical
severity and outcome were independent of the
aetiological agents detected.
INTRODUCTION
Community-acquired pneumonia (CAP) is a world-
wide cause of morbidity and mortality.1–3 In spite
of the advances in diagnostics, the aetiology of
CAP often remains uncertain and therapy is empir-
ical.4 5 The low sensitivity of blood and sputum
cultures and the presence of a heterogeneous bac-
terial ﬂora in the upper respiratory tract confound
the interpretation of the tests.6 Respiratory viruses
are the worldwide cause of acute lower respiratory
tract infections (ALRIs) in children and their
speciﬁc diagnosis is often made by immunodiag-
nostic techniques. In children, unlike in adults, an
aetiological diagnosis is easily assessed by many
diagnostic techniques because viral shedding is
high and prolonged.7 8 The development of
molecular methods with improved sensitivity and
speciﬁcity has paved the way for the detection of
new viruses, for the identiﬁcation of pathogens
that are difﬁcult to culture, and for the detection
of pathogens later in the disease process.
Molecular diagnostics have improved our under-
standing of ALRIs in children and in adults.9–12
Seasonality of ALRIs is similar in paediatric and
adult respiratory illnesses, suggesting a similar aeti-
ology. In prior reports we presented the epidemi-
ology and clinical impact of Mycoplasma
pneumoniae and respiratory syncytial virus (RSV)
in Chilean adults with CAP.13–15 Here we present
a comprehensive evaluation of the bacterial and
viral aetiology of CAP in adults. We postulate that
viruses and atypical bacteria either as sole or coin-
fections play a relevant role in adult CAP and that
molecular diagnostics will deﬁne the speciﬁc aeti-
ology in a majority of cases. We also explore the
relationship between respiratory pathogen and
clinical severity with a validated severity score
index.16
Key messages
What is the key question?
▸ Viruses and atypical bacteria were frequently
detected as single and mixed agents in adults
with community-acquired pneumonia (CAP).
What is the bottom line?
▸ Although agent detection increased notably by
PCR diagnosis, clinical severity and outcome
were independent of the pathogenic agents
detected.
Why read on?
▸ Although adult CAP is a relevant worldwide
cause of morbidity and mortality, the aetiology
often remains uncertain and the therapy is
empirical.
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METHODS
Patients and study design
A prospective study was conducted in patients ≥18 years of age
presenting with CAP in two hospitals in Santiago, Chile from
February 2005 to December 2007. The study was approved by the
University of Chile and Health Institutional Ethics Committee and
all subjects at enrolment gave written informed consent. CAP was
deﬁned by the presence of acute respiratory symptoms for less
than 1 week and chest radiography showing new pulmonary inﬁl-
trates. Exclusion criteria included immunocompromising condi-
tions (ie, HIV, active treatment for cancer, organ transplant,
immunosuppressive therapy) and hospitalisations within 30 days
preceding enrolment. Information on age, gender, smoking status,
prior antibiotic treatment, comorbidities and clinical presentation,
vital signs, laboratory parameters, antimicrobial therapy and hos-
pital course were recorded for all patients in standardised ﬁles.
Chest radiographic patterns were described by independent radiol-
ogists as alveolar, interstitial or mixed inﬁltrates; the extension was
categorised according to the number of lobes involved and the
presence of pleural effusion. Patient severity was assessed during
the ﬁrst 48 h after enrolment by the pneumonia severity index
described by Fine.16 The illness outcome and the presence of com-
plications like renal failure, shock, mechanical ventilation and
others were recorded. Patients who died between admission and
30 days after discharge were recorded.
Sample collection
In addition to routine laboratory tests, such as complete blood
cell count, biochemistry panel, oxygen saturation at admission,
patients had collection of urine and blood for bacterial culture
and acute serum sample for serology. Induced sputum and naso-
pharyngeal aspirate were obtained and immediately transported
on ice to the laboratory for bacterial and viral diagnostics.
Aliquots were prepared and stored at −80°C for later testing.
Participants were contacted at 4–6 weeks for follow-up and col-
lection of convalescent sera. Serum samples were processed
immediately and stored at −20°C until tested.
Viral study
Specimen processing
Sample aliquots of respiratory secretions were prepared for
immunoﬂuorescent assay, viral isolation in cell culture and real
time PCR.
Viral isolation
Each specimen was processed as previously described.10 Brieﬂy,
samples were inoculated onto HEp-2 and Madin–Darby canine
kidney (MDCK) cell cultures and observed for development of
cytopathic effect (CPE) for 1 week, after which conﬁrmatory
immunoﬂuorescence assays (IFAs) for RSV, adenovirus, inﬂuenza
and parainﬂuenza viruses were performed in both cell cultures
with and without CPE.
Indirect immunoﬂuorescence assay
Smears were prepared in triplicate and IFA was performed for
RSV, adenovirus, inﬂuenza A and B, parainﬂuenza virus 1–3 as
described elsewhere, using monoclonal antibodies kindly pro-
vided by L Anderson (CDC, Atlanta) and P Pothier (Dijon,
France). We used commercial conjugate (Sigma) and virus-
speciﬁc monoclonal antibodies (Chemicon) for inﬂuenza and
parainﬂuenza virus typing.7 8
Serology
Serum haemagglutination inhibition (HI) test for antibodies to
inﬂuenza (H3N2, H1N1 and B) was performed as described
elsewhere.17 Paired sera were inactivated with receptor-
destroying enzyme ( Denka Seiken Corporation, Tokyo, Japan),
incubated overnight at 37°C, and heated at 56°C for 30 min.
A 0.5% turkey red blood cell suspension, control antigens and
reference antisera were used. Cases displaying at least a fourfold
rise between the acute and convalescent sera were recorded as
acute infection.
Sera were tested for antibodies to RSV and human metapneu-
movirus (hMPV) by microneutralisation assays to RSV/A/Tracy
(A2 like virus) and RSV/B/18537 (prototype B virus) to measure
RSV/A and RSV/B speciﬁc neutralising antibodies as previously
described.18 hMPV antibodies were also detected by ELISA
assays.19 Seroconversion was deﬁned by at least a fourfold rise
of antibody titre between acute and convalescent sera by one or
more of the serological tests.
Reverse transcriptase PCR for RSV and hMPV
Samples were treated with guanidinium thiocyanate-phenol-
chloroform method for RNA extraction.20 cDNA was synthesised
with 5 μL RNA (sample) and 0.52 μM F gene primer (F844:
50-TGTCTAACTATTTGAACA-30) for RSV and 10 μL RNA and
0.52 μM random hexamer primer (Amersham Bioscience) for
hMPV, during 1 h at 37°C, followed by 5 min at 95°C in a
AmpPCR System 2400. For RSV, a sequence of the N gene was
ampliﬁed with 10 μM (each) of N1 and N2 primers,21 1× Master
SYBR Green I (Roche) and 2 μL of cDNA. For hMPV, a sequence
of the N gene were ampliﬁed with 0.5 μM (each) of N2 and N3
primers.22 Cycling conditions included a denaturation step of
10 min at 94°C, followed by 50 (RSV) or 40 cycles (hMPV) of
10 s at 94°C, 5 s at 58°C (RSV) or 52°C (hMPV), 30 s at 72°C in a
Light Cycler 1.5 instrument (Roche). Amplicons were analysed by
melting curve analysis. Appropriated controls were included in
each assay.
Reverse transcriptase PCR for rhinovirus and coronavirus detection
Human coronavirus (HCoV), and picornavirus (PV) were
detected by real time reverse transcriptase PCR (RT-PCR) by
amplifying the conserved region of the replicase 1a gene and
the 50NCR conserved region, respectively, as previously
described.23 24 The 390 bp fragment of PV was puriﬁed and
sequenced using the kit ABI PRISM Dye Terminator Cycle
Sequencing ready Reaction in the automated sequencer ABI
model 377 (Applied Biosystems, Inc, USA). Sequences were
aligned to other sequences in the Gene Bank using the pro-
gramme Blast to differentiate between rhinovirus and
enterovirus.
Bacterial study
Cultures
Sputum samples displaying >25 leukocytes and <10 epithelial
cells per 100× power ﬁeld after Gram staining were cultured
and processed according to standard techniques.6 25 Urinary
antigens for Streptococcus pneumoniae were detected using
immunochromatographic tests (Binax NOW, Portland, Oregon,
USA).26 For Legionella species isolation, a subset of 256
samples were inoculated onto BCYE and GVPC media (Oxoid)
and incubated at 37.8°C for up to 10 days; 125 of these cases
were also studied for urinary antigen using immunochromato-
graphic tests.27 Conﬁrmatory PCR was performed on positive
samples as described elsewhere.28
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Polymerase chain reaction
Chlamydophila pneumoniae was detected using a nested PCR
directed to a chromosomal DNA segment (PstI 474) using the
reference strains AR-39, TW-183 and CM-1 as positive controls.
Primers HL and HR were used for the ﬁrst PCR and nested
PCR was performed as described elsewhere.29 30 For M pneu-
moniae a PCR directed to a 277 bp fragment of the 16S rRNA
gene was used, including a M pneumoniae FH strain as positive
control.14 31
Serology
Serum samples were tested for IgM and IgG antibodies by indir-
ect IFA using commercial kits. Sera were absorbed with an anti-
human IgG reagent (Zorba, Zeus, Inc, USA) prior to IgM
testing. The Chlamydia kit (SeroFIA, Sayvon, Israel) was used
for C pneumoniae and IgM ≥1 : 16 or a fourfold rise in IgG
titres between paired sera were regarded as acute infection;
single or standing IgG titres ≥1 : 512 were considered as past
infections. For M pneumoniae another IFA test was used (Zeus,
USA) and acute infection was assigned with IgM ≥1 : 32 or sero-
conversion in paired sera.32 Sera determinations were done
blindly with respect to other viral or bacterial tests.
Statistical analysis
Analysis was performed using the Z-test for categorical data and
the t test, Mann–Whitney rank sum or Kruskal–Wallis one-way
analysis of variance for continuous variables. The level of signiﬁ-
cance was set at p<0.05. Data were analysed using SigmaStat
software.
RESULTS
Patients and samples
Respiratory secretions and urine were obtained from 356
patients from 330 hospitalised and 26 ambulatory cases.
Good-quality sputum samples were available for 233 (65%)
cases. Blood culture was performed in 241 (75%) patients and
paired sera were available for 211 (68%) patients. Rhinovirus
and coronavirus were studied in a subset of 268 cases from
August 2005 to September 2007. Serology for inﬂuenza was
performed only in cases with paired sera, which covered the
three annual seasonal inﬂuenza epidemics. A respiratory patho-
gen was detected in 232 (65.2%) of 356 cases, corresponding to
bacteria in 92 (26%) and viruses in 80 (22%) cases. Mixed
viral/bacterial infections were detected in 60 (17%) cases. In
124 (35%) patients no agent was detected (table 1). Death
occurred in 28 (7.8%) cases, without signiﬁcant difference
between those with or without a detected infectious agent.
Clinical characteristics of population
Demographic risk factors, comorbidities and outcomes were not
signiﬁcantly different between those with or without a detect-
able pathogen (table 2). Also laboratory parameters like haemo-
gram, glucose, electrolytes, urea and liver function enzymes did
not exhibit signiﬁcant differences (data not showed). Only
C-reactive protein was signiﬁcantly higher in patients with a
detectable pathogen (median=211 mg/dL) compared with
patients without an identiﬁable pathogen (median=158 mg/dL)
(p=0.01), although with a broad range in values (table 2).
The clinical outcome related to the presence of complications,
like radiologic progression, respiratory failure, need for mechan-
ical ventilation or presence of shock, failed to show any signiﬁ-
cant difference between both groups. Only liver damage
(14/221=6.3% vs 1/119=0.8%; p=0.03) was signiﬁcantly
Table 1 Distribution of 356 adults with community-acquired pneumonia by
infection classification
Infection classification N %
Negative cases 124 34.8
Only bacteria* 92 25.8
Only viruses* 80 22.5
Mixed† 60 16.9
Santiago, Chile, February 2005–December 2007.
*One or more agents per case.
†Mixed virus and bacteria, with one or more agents per case.
Table 2 General characteristics of 356 patients with community-acquired
pneumonia, according to detection of an infectious agent
Characteristic With agent Without agent
p
Value*
N 232 124
Age (years), median (range) 61 (18–94) 66 (18–93) 0.1
Men, n (%) 128 (55.2) 63 (50.8) 0.4
Death, n (%) 17 (7.3) 11 (8.9) 0.6
Hospital stay (days), median/
n (range)
7/190 (1–71) 7/104 (1–82) 0.3
Hospitalisation, n (%) 211 (90.9) 119 (96.0) 0.1
ICU admission, n (%) 53 (22.8) 30 (24.2) 0.7
Outpatients, n (%) 21 (9.1) 5 (4.0) 0.1
Smokers, n (%) 90/220 (40.1) 37/119 (31.1) 0.1
Alcohol use >80 g/day, n/N
(%)
31/221 (14) 11/119 (9.2) 0.2
Comorbidity, n (%) N=221 N=119
Any 112 (50.7) 66 (55.5) 0.4
Diabetes mellitus 36 (16.3) 19 (15.9) 0.9
COPD 36 (16.3) 23 (19.3) 0.5
Asthma 12 (5.4) 4 (3.4) 0.5
Cardiac failure 38 (17.2) 23 (19.3) 0.7
Liver damage 14 (6.3) 1 (0.8) 0.03
Renal disease 4 (1.8) 7 (5.9) 0.08
Antibiotics prior to
admission, n/N (%)
48/220 (21.8) 24/119 (20.2) 0.8
Mental confusion, n/N (%) 55/219 (25.1) 22/115 (19.1) 0.2
Hypotension, n/N (%) 36/218 (16.5) 26/119 (21.9) 0.2
Shock, n/N (%) 21/217 (9.7) 9/119 (7.6) 0.6
Respiratory rate, median/n
(range)
24/172 (18–48) 24/99 (15–46) 0.8
Pulse, median/n (range) 95/214 (17–153) 91/119 (10–180) 0.1
Systolic blood pressure
(mm Hg), median/n (range)
120/178 (68–213) 123/178 (70–195) 0.6
Temperature at admission (°
C), median/n (range)
37.2/219 (35–41) 37.4/117 (35–40.5) 0.9
C-reactive protein (mg/dL),
median/n (range)
211/182 (2–569) 158/101 (3–454) 0.02
Chest radiograph, n (%) N=217 N=115
Interstitial patterns 31 (14.3) 12 (10.4) 0.4
Alveolar patterns 173 (79.7) 95 (83.3) 0.5
Both 13 (5.9) 8 (6.9) 0.9
Multilobar involvement 70 (32.6) 42/113 (37.2) 0.4
Santiago, Chile, February 2005–December 2007.
*p by Kruskal–Wallis test.
COPD, chronic obstructive pulmonary disease; ICU, intensive care unit.
1002 Luchsinger V, et al. Thorax 2013;68:1000–1006. doi:10.1136/thoraxjnl-2013-203551
Respiratory infection
higher in patients with a detectable pathogen (table 2).
However, clinical severity of cases correlated with parameters
classically described, like age, comorbidity, hypotension, hepatic
failure and others (table 3).
Viral and bacterial agent detection
The most commonly identiﬁed bacteria was S pneumoniae
(75=21.1%), although it was the sole pathogen in 38 cases
(table 4). Of these 75 patients, 39 were tested by sputum
culture, 61 by blood culture and 73 by urine antigen detection,
and S pneumoniae was identiﬁed in 12 (30.8%), 15 (24.6%)
and 60 (82.2%) cases, respectively.
M pneumoniae and C pneumoniae were detected in 32 (9%)
and 28 (7.9%) cases, respectively, but only in 13 cases for each
agent were they the sole pathogen. For M pneumonia, PCR and
serology yielded similar results (69.7% and 72.7%, respectively;
42.4% of cases were positive by both tests). C pneumoniae was
detected by PCR (19/28) and serology (15/28), with 6 of 28
cases (21.4%) detected by both tests. Legionella pneumophila
was detected in 13/256 cases (5.07%), 3 by culture, 10 by
antigen detection (one by both); all cases were conﬁrmed by
PCR. The most commonly detected viruses were RSV (n=48),
PV (n=41) and hMPV (n=41), but single infections occurred in
only 18, 17 and 8 cases, respectively (table 4).
Yield of different techniques for viral diagnosis
Detection of a viral pathogen by conventional IFA and cell
culture techniques was infrequent, with only 2 of 48 RSV infec-
tions and 6 of 27 inﬂuenza cases. The RT-PCR technique identi-
ﬁed 32 RSV cases. The microneutralisation serology for RSV
and HI for inﬂuenza detected seroconversion in 20 of 184
(10.8%) and 26 of 211 (12.8%) adults with paired sera, respect-
ively. RT-PCR was the only test applied for hMPV, PV and cor-
onavirus diagnosis, resulting in the detection of 41 (11.5%), 41
(11.5%) and 20 (4.5%) cases, respectively (table 4).
Table 3 Clinical characteristics of 330 patients with community-acquired pneumonia admitted to ICUs or general wards
Clinical parameters ICU General Wards p Value*
N 83 247
Age (years), median (range) 68 (20–93) 63 (18–94) 0.06
Men, n (%) 39 (47.0) 138 (55.9) 0.2
Hospital stay (days), median/n (range) 116/80 (24–196) 6/195 (1–61) <0.001
Comorbidity, n (%) N=81 N=233
Any 56 (69.1) 118 (50.6) 0.006
Diabetes mellitus 19 (23.5) 66 (28.3) 0.4
Chronic obstructive pulmonary dis. 14 (17.3) 76 (32.6) 0.01
Asthma 1 (1.2) 26 (11.2) 0.01
Cardiac failure 22 (27.2) 55 (23.6) 0.6
Liver damage 7 (8.7) 13 (5.6) 0.7
Renal disease 5 (6.2) 8 (3.4) 0.7
Antibiotics prior to admission, n/N (%) 17/82 (20.7) 47/233 (20.2) 0.9
Infectious agent detected, n (%)
Virus 17 (20.5) 58 (23.5) 0.6
Bacteria 19 (22.9) 63 (25.5) 0.7
Virus–bacteria coinfection 17 (20.5) 37 (14.9) 0.3
Negative 30 (36.1) 89 (36.0) 0.9
Mental confusion, n/N (%) 45/82 (54.9) 32/230 (13.9) <0.001
Pleural effusion, n/N (%) 25/81 (30.9) 37/228 (16.2) 0.008
Hypotension, n/N (%) 40/80 (50.0) 19/231 (8.2) <0.001
Respiratory rate, median/n (range) 28/79 (18–36) 24/168 (16–40) <0.001
Pulse, median/n (range) 105/81 (73–142) 93/226 (41–180) <0.001
Systolic pressure (mm Hg), median/n (range) 110/79 (68–213) 122/174 (75–195) 0.006
Diastolic pressure (mm Hg), median/n (range) 60/78 (26–133) 70/174 (43–97) <0.001
Chest Rx multilobar involvement, n/N (%) 41/81 (50.6) 65/229 (28.9) <0.001
Fine score, n (%) N=83 N=247
1 5 (6.0) 64 (25.9) <0.001
2 6 (7.2) 59 (23.9) <0.001
3 15 (18.1) 53 (21.5) 0.6
4 24 (28.9) 62 (25.1) 0.6
5 33 (39.8) 9 (3.6) <0.001
Blood urea (mg/dL), median/n (range) 21/79 (8–116) 18/219 (6–75) <0.001
Chest Rx progression, n/N (%) 13/80 (16.3) 7/231 (3.0) <0.001
Hepatic failure, n/N (%) 8/80 (10.0) 1/231 (0.4) <0.001
Respiratory failure, n/N (%) 29/80 (36.3) 24/232 (10.3) <0.001
Shock, n/N (%) 27/80 (33.8) 3/231 (1.3) <0.001
Death during hospitalisation and until 30 days post discharge, n/N (%) 17/83 (20.5) 9/247 (3.6) <0.001
Santiago, Chile, 2005–2007.
ICU, intensive care unit.
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Seasonality
During the 36-month survey, respiratory viruses were circulating
with clear predominance of RSV during the three winter seasons
(May–July) (ﬁgure 1); inﬂuenza viruses presented as an epidemic
in autumn/winter and parainﬂuenza viruses had higher preva-
lence during the autumn months. This epidemiology is consistent
with the patterns previously reported in Chile.10 CAP peaked
during the winter months. It was inﬂuenced by the epidemiology
observed with S pneumoniae, RSV and inﬂuenza virus. Other
agents were endemic throughout the year (ﬁgure 1).
Clinical severity and infection classiﬁcation
The analysis of demographic and clinical parameters failed to
demonstrate a relationship between infection classiﬁcation (bac-
teria, virus or mixed coinfection) and illness severity outcome.
Furthermore, the presence of multiple pathogens did not con-
tribute to more severe disease (data not shown). Fine’s severity
score applied at admission also did not display differences
among the pathogenic groupings (table 5).
DISCUSSION
The aetiology of CAP in adults is not well understood. We
undertook this prospective study over a 3-year period in
Santiago to determine if comprehensive use of conventional and
molecular diagnostics would improve the aetiological
identiﬁcation of adult CAP and to determine if the aetiological
agent impacted disease severity. An aetiological agent was identi-
ﬁed in 65% of cases. S pneumoniae and RSV were the most
common bacterial and viral pathogens identiﬁed. Single and
coinfections occurred in 139 (39%) and 93 (26%) CAP cases,
respectively. Potentially vaccine-preventable pathogens (S pneu-
monia and inﬂuenza virus) were involved in 102 (28.7%) of the
356 CAP cases. The analysis was done globally, comparing
groups with and without a detectable infectious agent and by
infection classiﬁcation (viral, bacterial and mixed viral and bac-
terial) because sole infection by a few major pathogens was
uncommon.
Adult CAP was observed year round, with distinct winter sea-
sonality. Outbreaks of S pneumoniae, RSV and inﬂuenza contrib-
uted to the increase in adult CAP during the winter months.
Effective vaccines are available against inﬂuenza and S pneumo-
niae. Increased use of these vaccines could reduce the rates of
adult CAP, in particular during the winter months. In this study
information on vaccination history was not recorded.
Historically vaccination against inﬂuenza and S pneumoniae in
adults has not been well accepted by this population, even
though there are existing national recommendations for vaccin-
ating older adults and at-risk groups.
Comprehensive use of molecular diagnostics, serological
assays, urinary antigen tests, and induced sputum and blood
Table 4 Distribution of single and multiple viral and bacterial agents detected in 356 adults with community-acquired pneumonia
Bacterial agents
Only bacteria (n=92) Mixed bacterial and viral infections (n=60)
Only one Plus other bacteria Plus virus Plus virus and other bacteria
Total
N %
Streptococcus pneumoniae 38 6 25 6 75 21.1
Haemophilus influenzae 3 3 0.8
Moraxella catarrhalis 1 3 2 6 1.7
Gram(–)bacillus 1 2 2 5 1.4
Staphylococcus aureus 3 1 2 2 8 2.2
Streptococcus agalactiae 1 1 0.3
Mycoplasma pneumoniae 13 5 13 1 32 9.0
Chlamydia pneumoniae 13 5 4 6 28 7.9
Legionella pneumophila 7 2 4 13 5.07*
Subtotal cases with bacteria 80 152† 42.7
Viral agents
Only viruses (n=80) Mixed viral and bacterial infections (n=60)
Only one Plus other virus Plus bacteria Plus bacteria and other virus
Total
N %
RSV 18 8 12 10 48 13.5
hMPV 8 14 10 9 41 11.5
Flu 12 5 7 3 27 7.6
HCoV 3 9 3 5 20 5.6
Picornavirus 17 11 9 4 41 11.5
ADV 1 2 3 0.8
Subtotal cases with viruses 59 140‡ 39.3
No agent 124 34.8
Santiago, Chile, February 2005–December 2007.
*13/256 cases=5.07%.
†Cases with unique bacteria or with bacteria plus other agent were counted as one individual case.
‡Cases with unique virus or with virus plus other agent were counted as one individual case.
ADV, adenovirus; HCoV, human coronavirus; hMPV, human metapneumovirus; RSV, respiratory syncytial virus.
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cultures improved the overall detection of an infectious agent in
adults presenting with CAP. Viral and the atypical bacteria detec-
tion were as frequent as the classical S pneumoniae. There were
no antecedent symptoms or signs that could be associated with
one speciﬁc aetiological agent. In addition, chest radiograph
ﬁndings could not deﬁne the aetiology.
The identiﬁcation of a bacterial agent using sputum and
blood cultures was infrequent, and the detection of a bacterial
pathogen was improved with the use of the urinary antigen
assay for S pneumoniae. The implementation of molecular diag-
nostic technology has enhanced and broadened the spectrum of
potential aetiological agents because of the improved identiﬁca-
tion of known agents and the recognition of new agents asso-
ciated with respiratory illnesses.33 34 In virology, molecular
techniques are extensively used and for some agents they consti-
tute the principal method for identiﬁcation (ie, hMPV, PV, cor-
onavirus). Furthermore, the diminished load and shorter
duration of viral shedding that occurs in adults compared with
children makes the use of highly sensitive diagnostic tools neces-
sary in adults. For atypical bacteria, PCR should be used as the
primary diagnostic technique; unfortunately, its application is
often restricted to major academic and diagnostic centres.
To our surprise, we were unable to ﬁnd a relationship
between illness severity and major pathogenic grouping or infec-
tion classiﬁcation. Most of the agents detected occurred more
frequently with other pathogens than as the sole pathogen. We
detected many infectious agents using new diagnostic technol-
ogy, but the translation of this ﬁnding was not clear. The detec-
tion of traditional pathogens, like S pneumoniae and atypical
bacteria, could explain the clinical outcome, but the detection
of RSV and hMPV, recognised viral respiratory pathogens in the
paediatric population, must be carefully considered in adults.
The identiﬁcation of other viruses such as rhinoviruses and cor-
onaviruses makes it more difﬁcult to assign an aetiological inter-
pretation because asymptomatic infections and prolonged viral
shedding can also occur. The frequent detection of two or more
infectious agents could be the more likely situation in CAP com-
pared with the classical assignation of a single agent to a patho-
genic outcome.34 Clinical or radiological features are not
characteristic of S pneumoniae CAP. In this study nearly 50% of
S pneumoniae cases occurred as coinfections. This ﬁnding sug-
gests that the classical presentation of pneumoccocal CAP as the
sole pathogen might not be correct and that other pathogens are
likely to contribute to the disease. Today the use of more sensi-
tive diagnostic technology is rendering it difﬁcult to make a
simple association between agent and illness.
In summary, factors such as age and comorbidities are rele-
vant to the severity of CAP. Despite improvements in identifying
an aetiological agent associated with CAP, we were unable to
demonstrate a clinical signiﬁcance during the acute process. The
relevant detection of classic, atypical bacteria and viruses should
be considered in the initial empirical antimicrobial intervention.
Figure 1 Monthly distribution of 356 adults presenting with
community-acquired pneumonia, according to infectious agent
identiﬁed in Santiago, Chile, February 2005 to December 2007.
(A) Cases with and without a detectable infectious agent. (B) Cases
associated with a bacterial pathogen (Streptococcus pneumonia (Sp),
Mycoplasma Pneumonia (Myco), Chlamydia pneumonia (Chlam).
(C) Cases associated with a viral pathogen ( respiratory syncytial virus
(RSV), inﬂuenza (Flu), picornavirus (PV), coronavirus (HCoV),
metapneumovirus (hMPV)).
Table 5 Clinical severity according to Fine score and infection classification in 356 adults with community-acquired pneumonia
Fine class
Total cases Without agent With agent Bacteria Virus
Bacteria and
virus
N % N % N % N % N % N %
1 84 23.6 24 19.4 60 25.9 38 25.0 33 23.6 11 18.3
2 74 20.8 28 22.6 46 19.8 25 16.4 31 22.0 10 16.7
3 69 19.4 29 23.4 40 17.2 27 17.8 28 21.3 15 25.0
4 87 24.4 33 26.6 54 23.3 39 25.7 31 22.0 16 26.7
5 42 11.8 10 8.1 32 13.8 23 15.1 17 12.1 8 13.3
Total 356 100 124 34.8 232 65.2 152 42.7 140 39.3 60 16.9
Santiago, Chile, February 2005–December 2007.
Statistical analyses were performed using Z test, p>0.1.
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Atypical bacteria were detected in approximately 20% of cases,
justifying antimicrobial coverage. The seasonality of viral
respiratory agents should also inﬂuence the recommendation for
inﬂuenza antiviral therapy.
In conclusion:
1. Viruses and atypical bacteria are detected as frequently as S
pneumoniae in patients with CAP if modern diagnostic tech-
nology is applied.
2. We were unable to demonstrate that either type of infection
(bacterial vs viral) or number of pathogens (sole vs coinfec-
tions) adversely affected clinical outcome.
3. The detection of multiple infectious agents in adult CAP is
common and should be considered in the selection of empir-
ical antimicrobial therapy.
4. Vaccination against inﬂuenza and S pneumoniae can reduce
adult CAP admission, especially during the winter season.
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